The Reality and Prospects of Co-Creation Drug Discovery Centered on Academia, Drug Discovery Ventures, and Pharmaceutical Companies
Yuji Takasuna ( The Office of Pharmaceutical Industry Research Senior Researcher)
(No.81: Published in October, 2023)
In recent years, satisfaction with drugs for lifestyle-related and other diseases has improved, and most of the drug discovery targets tackled in the past have been fully researched, making it increasingly difficult for R&D-oriented pharmaceutical companies to create innovative drugs and medical technologies on their own. On the other hand, academia and drug discovery ventures are making remarkable progress in new drug discovery technologies, including new modalities, and it is essential for pharmaceutical companies to co-create with them.
In this report, we surveyed and analyzed the actual status of "co-creation drug discovery," or drug discovery utilizing alliances among academia, drug discovery ventures, and pharmaceutical companies, from various perspectives, focusing particularly on the status of acquisition of drug seeds and technologies from external sources. The report then presents an image of co-creation drug discovery in Japan, and outlines the position of Japanese companies in the co-creation of drug discovery, where companies from around the world are competing for the top spot.